SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
ALKS - Alkermes, Inc.
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
189 19 0 ALKS
Emcee:  jmhollen Type:  Moderated
Introduction Market Data Compact
Alkermes, Inc. (Nasdaq ALKS): fills a distinctive role in the pharmaceutical industry, delivering unique solutions for some of the world's most pressing diseases. With one product on the market, a second product launch planned for the second quarter of 2006, and a strong pipeline of partnered and proprietary product candidates, we are realizing the promise of our valuable proprietary drug delivery technologies and improving the lives of patients worldwide.
Website: investor.alkermes.com
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
189Closed position at $14.00...never thought this one would turn out, considering tArthur Radley-3/15/2010
188Took a small position this morning $12.40---IMO they will get approval but mightArthur Radley-3/12/2010
187>>Alkermes and Lilly Expand AIR(R) Inhaled Insulin Collaboration Monday Jatuck-1/8/2007
186Bears Focusing on Alkermes Technical Analysis By Chris Schumacher RealMoney.coDoc Bones-1/4/2007
185The one year chart on this is looking dismal.. [ALKS] down from 26 to 14 for neashortsinthesand-12/20/2006
184haha. Yup, slow start, awful start.rkrw-11/3/2006
183<i>My personal opinion is I'd call $300M/year pretty successful</i&DewDiligence_on_SI-11/2/2006
182JNJ’s new drug (the one rkrw mentioned) will make Consta irrelevant. You can detDewDiligence_on_SI-9/8/2006
181>>regarding air insulin, the premise is simply it's a more patient frituck-9/8/2006
180Tuck, I haven't kept up with alks very well lately, I sold out of it a whilerkrw-9/8/2006
179rkrw, I know you have followed this and seen possibilities for Risperdal Constatuck-9/8/2006
178Press Release Source: Valera Pharmaceuticals, Inc. Valera Pharmaceuticals Filerkrw-6/27/2006
177<i>>Just wondering what you think the peak sales for vivitrex will be. DewDiligence_on_SI-6/19/2006
176I have no position in alks. Just wondering what you think the peak sales for vrkrw-6/19/2006
175What is your position in ALKS? You’ve come to the company’s defense many times oDewDiligence_on_SI-6/19/2006
174Whatever you say. I don't think the co's will drop the drug after the rkrw-6/15/2006
173<i>Upfront fee wasn't to offset risk, it was to offset the launch costDewDiligence_on_SI-6/15/2006
172Drug Abuse Sciences and alks were pretty much neck and neck a few years ago but rkrw-6/15/2006
171Good thing ALKS offloaded much of the Vivitrol risk onto CEPH by getting an amplDewDiligence_on_SI-6/15/2006
170UPDATE 1-France's DrugAbuse aims to raise $25 mln in IPO Wed Jun 14, 2006 9:rkrw-6/14/2006
169More on the nosebleed pricing model :-) What Price Sobriety? By Robert Steyerrkrw-5/25/2006
168Not sure how relevant that will be 1/month and since they won't be self admirkrw-5/22/2006
167By the way, Vivitrol does not use an itty bitty needle—it’s a 21-23 gauge and isDewDiligence_on_SI-5/22/2006
166Agreed, the pricing is nuts. Given the pricing I think they'll be disappointrkrw-5/22/2006
165>At the (nosebleed) price they're charging that's only about an avg ofred hayes-5/22/2006
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News